Education research activities

■ Journal

1.		Growth potency of microvascular components in gliomas immunohistochemical double stain for proliferating cell antigen and laminin. 1994/04
2.		Monocyte chemoattractant portein-1 (MCP-1) gene transduction ; an effective tumor vaccine strategy for non-intracranial tumors. 1995
3.		Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide 1996
4.		Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to cytotoxic effects of cytosine arabinoside 1996
5.		Effect of adenoviral-mediated thymidine kinase transduction and ganciclovir therapy or tumor-associated endothelial cells. 1997
6.		Induction of antigen-specific antitumor immunity with adenoviral-transduced dendritic cells 1997
7.		Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector 1997
8.		Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth 1997
9.		Cell proliferation and apoptosis in human middle ear cholesteatoma 1998
10.		The inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis 1998
11.		Viral vector-targeted "anti-angiogenic" gene therapy utilizing an angiostatin complementary DNA 1998
12.		Cotransfection of poly (I:C) and siRNA of IL-10 into fusions of dendritic and glioma cells enhances antitumor T helper type I induction in patients with gliomas. 2011/02
13.		Compartment syndrome associated with vascular avulsion caused by transradial access in neurointervention of unruptured intracranial aneurysm. 2023
14.		Contrast injection from an intermediate catheter placed in an intradural artery is associated with contrast-induced encephalopathy following neurointervention. 2023
15.		Efficacy and safety of fetal posterior cerebral artery stented coil embolization for fetal posterior cerebral aneurysms. 2023
16.		Intermediate catheter is associated complete occlusion and dense packing in coil embolization of unruptured cerebral aneurysms. 2023
17.		Prediction of difficulty of transradial approach to the left internal carotid artery in nurointervention. 2023
18.		Risk Factors for radial artery occlusion after neurointervention for unruptured intracranial aneurysm via transradial access. 2023
19.		FMISO-PET and immunohistochemistry verified tumor oxygenation, stemness, and immunosupportive microenvironment after preoperative neoadjuvant bevacizumab for newly diagnosed glioblastoma. 2023/05
20.		Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma. 2023/06
21.		An exploratory and prospective phase I/II study of combined therapy with preoperative neoadjuvant bevacizumab for patients with newly diagnosed glioblastoma. 2023/12
22.		Local thrombolytics via balloon-assisted intra-arterial infusion as a rescue therapy for thromboembolism during endovascular coil embolization. 2023/12
23.		Intermediate catheter is associated complete occlusion and dense packing in coil embolization of unruptured cerebral aneurysms. 2024/01
24.		An exploratory and prospective phase I/II study of combined therapy with preoperative neoadjuvant bevacizumab for patients with newly diagnosed glioblastoma. 2024/03
25.		Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment. 2024/04
26.		White collar sign after coil embolization of unruptured intracranial aneurysms assisted by the Neuroform atlas stent. 2024/04
27.		TIPS and technical nuances of digital illustration in neurointerventional surgery. 2024/07
28.		Comparative analyses of immune cells and alpha-smooth muscle actin positive cells under immunological microenvironment between with and without dense fibrosis in primary central nervous system lymphoma. 2024/08
29.		Intermediate catheter use is associated with intraprocedural rupture during coil embolization of ruptured cerebral aneurysms: A retrospective propensity score-matched study. 2024/08
30.		Response to correspondence on an exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma. 2024/08
31.		Comparative volumetric analyses following bevacizumab therapy for a patient with co-incidence of glioblastoma, meningioma, and dural arteriovenous fistula: A case report and review of literature 2024/09
32.		Significance and priority of surgical resection as a therapeutic strategy based on clinical characteristics of brain metastases from renal cell carcinoma. 2024/09
33.		Comparative analyses of erythroblast transformation specific-1 gene (ERG) expression before and after neoadjuvant bevacizumab therapy for newly diagnosed glioblastoma 2024/10
34.		Abnormal Vessels Potentially Accelerate Glioblastoma Proliferation by Inducing the Protumor Activation of Macrophages 2025/02
35.		Differences in neuroradiological impacts of hematoma volume and midline shift on clinical symptoms and recurrence rate in patients with unilateral chronic subdural hematoma. 2025/02
Display 5 items
Display all(35)

■ BooK

1.		Advantages of the new type of high viscosity polymer plastic (CEMEX Isoplastic) for the cranioplasty., Bone Cements and Cemented Fixation of Implants 2001
2.		Advantage of surgical treatment for intracranial dural arteriovenous fistulas : Clinical experience and Review of literatures, Fistulas and Fissures:Types, Symptoms, Causes, and Treatment 2013
3.		Development and perspectives of histopathological findings of glioblastoma treated by bevacizumab., Advances in Medicine and Biology 2019
4.		Surgical wound management following craniotomy with attention to bevacizumab therapy., Advances in Medicine and Biology 2019

■ Academic background

1.

1985/04～1991/03

Faculty of Medicine, Jikei University, Graduated

■ Presentation

1.	Immunotherapy of malignant gliomas using tumor vaccines consisting of irradiated 9L cells transduced with the MCP-1 gene. （Poster notice，General） 1994/09/21
2.	Immunotherapy of malignant gliomas using tumor vaccines consisting of irradiated 9L cells transduced with the MCP-1 gene. （Poster notice，General） 1995/04/22
3.	Therapeutic efficacy of retroviral mediated gene transfer of cytochrome P450 2B1 in the 9L gliosarcoma brain tumor model. （Poster notice，General） 1995/05/05
4.	9L cells transduced with the monocyte chemoattractant protein-1 (MCP-1) gene as a novel tumor vaccine for malignant gliomas. （Speech，General） 1995/05/21
5.	Anti-angiogenesis gene therapy with platelet factor 4 against malignant gliomas. （Speech，Panelist at Symposium/Workshop (Appointed)） 1995/06/03
6.	Deoxycytidine kinase (dCK) as a “Suicide” gene proposal : dCK-AraC system for cancer gene therapy. （Speech，General） 1995/11/10
7.	Inhibition of angiogenesis and tumor growth by retroviral mediated modified PF4 cDNA transduction. （Poster notice，General） 1996/04/01
8.	Inhibition of angiogenesis and tumor growth following retroviral-mediated transduction of a modified platelet factor 4 cDNA. （Speech，General） 1996/04/21
9.	Gene therapy for malignant gliomas using retroviral and adenoviral vectors encoding cytochrome P450 2B1 together with cyclophophamide. （Poster notice，General） 1996/04/27
10.	Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1gene together with cyclophosphamide. （Speech，General） 1996/06/22
11.	Retroviral mediated modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. （Poster notice，General） 1996/09/04
12.	Retroviral and adenoviral mediated modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. （Poster notice，General） 1996/09/25
13.	Targeted gene expression in gliomas using an E2F-responsive adenoviral vector. （Poster notice，General） 1996/09/25
14.	Retroviral and adenoviral mediated angiostatin cDNA inhibits angiogenesis and tumor growth. （Speech，Panelist at Symposium/Workshop (Applied)） 1997/04/12
15.	Viral vector-mediated anti-angiogenesis gene therapy by angiostatin cDNA. （Speech，Panelist at Symposium/Workshop (Appointed)） 1997/08/16
16.	Effect of adenoviral-mediated thymidine kinase transduction and ganciclovir therapy on tumor-associated endothelial cells. （Poster notice，General） 1997/10/08
17.	Angiogenesis targeted gene therapy by angiostatin cDNA. （Poster notice，General） 1997/10/22
18.	Angiogenesis targeted gene therapy utilizing angiostatin cDNA. （Poster notice，General） 1998/01/24
19.	Effect of adenoviral-mediated thymidine kinase transduction on tumor-associated endothelial cells. （Speech，General） 1998/03/28
20.	Viral vector-mediated anti-angiogenesis therapy utilizing endogenous angiogenesis inhibitors as a novel gene therapy for malignant gliomas. （Poster notice，General） 1998/09/19
21.	Anti-angiogenesis gene therapy utilizing endogenous angiogenesis inhibitors. （Speech，Panelist at Symposium/Workshop (Appointed)） 1999/11/20
22.	Anti-angiogenic therapy of malignant ascites using an adenoviral vector expressing secreted platelet factor 4. （Poster notice，General） 2000/04/03
23.	Treatment of malignant ascites with adenoviral vectors expressing antiangiogenic genes. （Speech，General） 2000/05/31
24.	Adenoviral mediated antiangiogenic gene therapy of malignant ascites in breast and ovarian cancer. （Speech，General） 2000/07/27
25.	Adenoviral mediated antiangiogenic gene therapy of malignant ascites in breast and ovarian cancer. （Poster notice，General） 2001/03/14
26.	Therapeutic efficacy of c-kit and PDGF receptor tyrosine kinase ihibitor STI 571 on glioma and metastatic brain tumors. （Poster notice，General） 2003/04/05
27.	Gene expression profile of glioblastoma cells from patients with long term survival treated with dendritic cell immunotherapy. （Speech，General） 2020/06/21
28.	Low expression of HLA-A as a novel prognostic factor in glioblastoma treated with tumor-fused dendritic cell vaccines. （Poster notice，General） 2022/11/17
29.	Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab. （Speech，Special/Invited Lecture） 2023/05/16
30.	A multicenter exploratory phase I/II study of neoadjuvant bevacizumab therapy for newly diagnosed malignant glioma. （Speech，Panelist at Symposium/Workshop (Applied)） 2023/10/21
31.	An exploratory multi-institutional prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed and recurrent glioblastoma. （Speech，Panelist at Symposium/Workshop (Appointed)） 2024/07/09
32.	A multicenter prospective exploratory phase II study of neoadjuvant bevacizumab for newly diagnosed malignant glioma （Poster notice，General） 2024/08/16
Display 5 items
Display all(32)

■ Business career

1.	1997/04～2009/08	The Jikei University School of Medicine The Jikei University School of Medicine Research Associate
2.	1994/01～1997/03	The Jikei University School of Medicine The Jikei University Graduate School of Medicine
3.	1993/04～1994/12	The Jikei University School of Medicine Research Center for Medical Sciences
4.	1991/06～1993/03	The Jikei University School of Medicine The Jikei University School of Medicine

■ Educational ability

● Practice example of education method
1.	2022/03～	glioma zoom meeting
2.	2023/08～	Kashiwa Neuro-Radio-Oncology Joint Meeting

■ Main Subject

neurosurgery

■ Lecturer and lecture

1.

2024/03/29

A role of surgery for metastatic brain tumor 〜Avoidance and improvement neuro-function, and pathological/molecular final diagnoses〜.